Jefferies Group's NBIX Position Overview
Jefferies Group (via Jefferies Financial Group Inc.) currently holds 45,976 shares of Neurocrine Biosciences, Inc. (NBIX) worth $6.52 M, representing 0.03% of the portfolio. First purchased in 2022-Q4, this medium-term investment has been held for 10 quarters.
Based on 13F filings, Jefferies Group has maintained a strategic position in NBIX, demonstrating sustained confidence in this investment. Largest addition occurred in Q4 2025, adding 45,976 shares. Largest reduction occurred in Q1 2023, reducing 14,511 shares.
Analysis based on 13F filings available since 2013 Q2
Jefferies Group's Neurocrine Biosciences (NBIX) Holding Value Over Time
Track share changes against reported price movement
Quarterly Neurocrine Biosciences (NBIX) Trades by Jefferies Group
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | +45,976 | New Buy | 45,976 | $141.83 |
| Q2 2025 | -4,500 | Sold Out | 0 | $0.00 |
| Q1 2025 | +4,500 | New Buy | 4,500 | $110.60 |
| Q4 2024 | -4,390 | Sold Out | 0 | $0.00 |
| Q3 2024 | -390 | Reduce 8.16% | 4,390 | $115.22 |
| Q2 2024 | -1,155 | Reduce 19.46% | 4,780 | $137.67 |
| Q1 2024 | -691 | Reduce 10.43% | 5,935 | $137.92 |
| Q4 2023 | +6,626 | New Buy | 6,626 | $131.76 |
| Q1 2023 | -14,511 | Sold Out | 0 | $0.00 |
| Q4 2022 | +14,511 | New Buy | 14,511 | $119.44 |
Jefferies Group's Neurocrine Biosciences Investment FAQs
Jefferies Group first purchased Neurocrine Biosciences, Inc. (NBIX) in Q4 2022, acquiring 14,511 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Jefferies Group has held Neurocrine Biosciences, Inc. (NBIX) for 10 quarters since Q4 2022.
Jefferies Group's largest addition to Neurocrine Biosciences, Inc. (NBIX) was in Q4 2025, adding 45,976 shares worth $6.52 M.
According to the latest 13F filing for Q4 2025, Jefferies Group's firm, Jefferies Financial Group Inc., owns 45,976 shares of Neurocrine Biosciences, Inc. (NBIX), valued at approximately $6.52 M.
As of the Q4 2025 filing, Neurocrine Biosciences, Inc. (NBIX) represents approximately 0.03% of Jefferies Group's publicly disclosed stock portfolio, making it one of their key holdings.
Jefferies Group's peak holding in Neurocrine Biosciences, Inc. (NBIX) was 45,976 shares, as reported at the end of Q4 2025.